Inflarx N V's Customers Performance

Name: Inflarx N V Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

IFRX

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


IFRX's Source of Revenues		During the corresponding time, Inflarx N V While revenue at the Inflarx N V's corporate clients • List of IFRX Customers

for the same period Inflarx N V

• List of IFRX Customers

Inflarx N V's Business Units

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Inflarx N V's Comment on Sales, Marketing and Customers

The company serves customers in the medical markets targeted for its product candidates, including GOHIBIC (vilobelimab). It faces challenges in obtaining coverage and adequate reimbursement from government-funded and private payors, impacting its revenue and profitability. The company has limited marketing, sales, and distribution capabilities. It initiated activities related to the FDA’s Emergency Use Authorization (EUA) for GOHIBIC in the United States but ceased active commercialization at the end of 2025 due to lack of commercial success. The company may need to establish or outsource marketing and sales functions to effectively commercialize its products.

News about Inflarx N V Contracts

Biopharmaceutical Company, InflaRx Pharmaceuticals, Launches Commitment Program to Improve Access to GOHIBIC for COVID-19 Patients

InflaRx Pharmaceuticals Inc., a subsidiary of InflaRx N.V., a biopharmaceutical company specializing in anti-inflammatory therapeutics targeting the complement system, has recently introduced the InflaRx Commitment Program. This program aims to broaden access to their product GOHIBIC (vilobelimab) for eligible patients. Under this program, institutions that meet the eligibility requirements will be refunded for up to six administered inpatient doses (the full treatment course) of GOHIBIC for patients who were administered the drug in line with its Emergency Use Authorization (EUA) and sadly passed away due to COVID-19 in the intensive care unit.The COVID-19 pandemic has put immense strain on healthcare syste...

Inflarx N V’s Comment on Sales, Marketing and Customers

IFRX's Stock Performance relative to it's Customers

IFRX's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Inflarx N V	140.30	0.03	-51.11	65
SUBTOTAL	0.00	0.00	0.00	-

Sources: Inflarx N V’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Inflarx N V’s corporate clients.
For your research, we’ve provided 9 tables on Inflarx N V corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.